Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986331 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1 Single Ascending Dose (SAD): Panel 1 | EXPERIMENTAL | - |
| Part 1 SAD: Panel 2 | EXPERIMENTAL | - |
| Part 1 SAD: Panel 3 | EXPERIMENTAL | - |
| Part 1 SAD: Panel 4 | EXPERIMENTAL | - |
| Part 1 SAD: Panel 5 | EXPERIMENTAL | - |
| Part 1 SAD: Panel 6 | EXPERIMENTAL | - |
| Part 1 SAD: Optional Split-dose Panel | EXPERIMENTAL | - |
| Part 2 Multiple Ascending Dose (MAD): Panel 1 | EXPERIMENTAL | - |
| Part 2 MAD: Panel 2 | EXPERIMENTAL | - |
| Part 2 MAD: Panel 3 | EXPERIMENTAL | - |
| Part 2 MAD: Panel 4 | EXPERIMENTAL | - |
| Part 2 MAD: Optional (to be determined) Panel | EXPERIMENTAL | - |
| Part 3 MAD in Japanese Participants (J-MAD): Panel 1 | EXPERIMENTAL | - |
| Part 3 J-MAD: Panel 2 | EXPERIMENTAL | - |
| Part 3 J-MAD: Panel 3 | EXPERIMENTAL | - |
| Part 3 J-MAD: Optional (to be determined) Panel | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986331 | DRUG | Specified dose on specified days |
| Placebo, Matching BMS-986331 | OTHER | Specified dose on specified days |
Inclusion Criteria: * No clinically significant deviations in medical history, physical examination, ECGs, vital signs, and clinical laboratory determinations * A body mass index of 18 - 32 kg/m2, inclusive * Women and men must agree to follow specific methods of contraception, if applicable For J...
BMS-986331 is an investigational small molecule being studied in healthy participants. It is being evaluated for safety, tolerability, drug levels, and drug effects. The drug is in Phase 1 clinical development and is not approved for any use.
BMS-986331 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials to evaluate the drug's safety and tolerability in healthy participants.
BMS-986331 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, with results not yet publicly reported.
BMS-986331 has one completed Phase 1 trial, NCT04444050, which evaluated the safety, tolerability, drug levels, and drug effects of the drug in healthy participants. The trial enrolled 48 participants in the United States and was randomized, double-blind, and controlled.
BMS-986331 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial in healthy participants was designed to assess safety and tolerability, but the drug has not been approved for any medical use.